Intelligence / Healthtech / New Clinical Trials / DR Healthcare - biotexia
Clinicaltrial registered13 Nov 2026
DR Healthcare - biotexia
13 Nov 2026: Trial registered · Effect of Oral Diamine Oxidase on Symptoms Induced by Histamine Oral Challenge. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 13 Nov 2026
- Title
- Effect of Oral Diamine Oxidase on Symptoms Induced by Histamine Oral Challenge
- Conditions
- Histamine Intolerance, Food Hypersensitivity, Histamine Sensitivity, DAO Deficiency
- Phase
- Not applicable
- Study Type
- Interventional
- Status
- Recruiting
- Countries
- Spain
- Country
- Spain
- Reference
- NCT07934953
- Location
- Spain
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at DR Healthcare - biotexia
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
More from Spain
New Clinical Trials
17 NovKinetic Performance S.L.trial registered · Effects of Zynamite S on Fatigue, Mood, Sleep, Safety, and Tolerability in Healthy AdultsClinical17 NovSinfatin S.Ltrial registered · Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke PatientsClinical16 NovAether Tech S.L.trial registered · Automated Oxygen Titration With the EMILY.AI Device During the Six-Minute Walk TestClinical12 NovAether Tech S.L.trial registered · Automated Versus Manual Oxygen Titration With the EMILY.AI Device in Hospitalized Patients With Acute Respiratory FailureClinical12 NovNovo Nordisk A/Strial registered · A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or BothClinical12 NovNovo Nordisk A/Strial registered · AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or BothClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.